KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas

D. Dias-Santagata, M. A. Selim, Y. Su, Y. Peng, R. Vollmer, A. Chłopik, G. Tell-Marti, K. M. Paral, S. C. Shalin, C. R. Shea, S. Puig, M. T. Fernandez-Figueras, W. Biernat, J. Rys´, A. Marszalek, M. P. Hoang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Few studies have addressed prognostic markers and none has correlated molecular status and prognosis in vulvar melanomas. Objectives: To evaluate the clinicopathological features of 95 cases of vulvar melanoma. Methods: p53, CD117, Ki-67, neurofibromin, brafv600e and nrasq61r immunostains, and molecular analyses by either targeted next-generation or direct sequencing, were performed on available archival materials. Results: Molecular testing detected mutations in KIT (44%), BRAF (25%), NF1 (22%), TP53 (17%), NRAS (9%) and TERT promoter (9%). Co-mutation of KIT and NF1 and of KIT and NRAS were identified in two and one cases, respectively. KIT mutations were significantly associated with better progression-free survival in univariate analyses. In multivariate analyses CD117 expression was significantly associated with better progression-free survival. Tumour thickness was significantly associated with worse progression-free and overall survival, and perineural invasion significantly correlated with reduced melanoma-specific survival and reduced overall survival. Cases were from multiple centres and only a subset of samples was available for molecular testing. Conclusions: KIT mutations and CD117 overexpression are markers of better progression-free survival. In addition to its prognostic value, molecular testing may identify cases that might respond to targeted agents or immunotherapeutic approaches.

Original languageEnglish (US)
JournalBritish Journal of Dermatology
DOIs
StateAccepted/In press - 2017

Fingerprint

Disease-Free Survival
Melanoma
Mutation
Neurofibromin 1
Multivariate Analysis
Neoplasms

ASJC Scopus subject areas

  • Dermatology

Cite this

KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. / Dias-Santagata, D.; Selim, M. A.; Su, Y.; Peng, Y.; Vollmer, R.; Chłopik, A.; Tell-Marti, G.; Paral, K. M.; Shalin, S. C.; Shea, C. R.; Puig, S.; Fernandez-Figueras, M. T.; Biernat, W.; Rys´, J.; Marszalek, A.; Hoang, M. P.

In: British Journal of Dermatology, 2017.

Research output: Contribution to journalArticle

Dias-Santagata, D, Selim, MA, Su, Y, Peng, Y, Vollmer, R, Chłopik, A, Tell-Marti, G, Paral, KM, Shalin, SC, Shea, CR, Puig, S, Fernandez-Figueras, MT, Biernat, W, Rys´, J, Marszalek, A & Hoang, MP 2017, 'KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas', British Journal of Dermatology. https://doi.org/10.1111/bjd.15836
Dias-Santagata, D. ; Selim, M. A. ; Su, Y. ; Peng, Y. ; Vollmer, R. ; Chłopik, A. ; Tell-Marti, G. ; Paral, K. M. ; Shalin, S. C. ; Shea, C. R. ; Puig, S. ; Fernandez-Figueras, M. T. ; Biernat, W. ; Rys´, J. ; Marszalek, A. ; Hoang, M. P. / KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. In: British Journal of Dermatology. 2017.
@article{5c5b2d71c0164ee9aa90fdcff0963d53,
title = "KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas",
abstract = "Background: Few studies have addressed prognostic markers and none has correlated molecular status and prognosis in vulvar melanomas. Objectives: To evaluate the clinicopathological features of 95 cases of vulvar melanoma. Methods: p53, CD117, Ki-67, neurofibromin, brafv600e and nrasq61r immunostains, and molecular analyses by either targeted next-generation or direct sequencing, were performed on available archival materials. Results: Molecular testing detected mutations in KIT (44{\%}), BRAF (25{\%}), NF1 (22{\%}), TP53 (17{\%}), NRAS (9{\%}) and TERT promoter (9{\%}). Co-mutation of KIT and NF1 and of KIT and NRAS were identified in two and one cases, respectively. KIT mutations were significantly associated with better progression-free survival in univariate analyses. In multivariate analyses CD117 expression was significantly associated with better progression-free survival. Tumour thickness was significantly associated with worse progression-free and overall survival, and perineural invasion significantly correlated with reduced melanoma-specific survival and reduced overall survival. Cases were from multiple centres and only a subset of samples was available for molecular testing. Conclusions: KIT mutations and CD117 overexpression are markers of better progression-free survival. In addition to its prognostic value, molecular testing may identify cases that might respond to targeted agents or immunotherapeutic approaches.",
author = "D. Dias-Santagata and Selim, {M. A.} and Y. Su and Y. Peng and R. Vollmer and A. Chłopik and G. Tell-Marti and Paral, {K. M.} and Shalin, {S. C.} and Shea, {C. R.} and S. Puig and Fernandez-Figueras, {M. T.} and W. Biernat and J. Rys´ and A. Marszalek and Hoang, {M. P.}",
year = "2017",
doi = "10.1111/bjd.15836",
language = "English (US)",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas

AU - Dias-Santagata, D.

AU - Selim, M. A.

AU - Su, Y.

AU - Peng, Y.

AU - Vollmer, R.

AU - Chłopik, A.

AU - Tell-Marti, G.

AU - Paral, K. M.

AU - Shalin, S. C.

AU - Shea, C. R.

AU - Puig, S.

AU - Fernandez-Figueras, M. T.

AU - Biernat, W.

AU - Rys´, J.

AU - Marszalek, A.

AU - Hoang, M. P.

PY - 2017

Y1 - 2017

N2 - Background: Few studies have addressed prognostic markers and none has correlated molecular status and prognosis in vulvar melanomas. Objectives: To evaluate the clinicopathological features of 95 cases of vulvar melanoma. Methods: p53, CD117, Ki-67, neurofibromin, brafv600e and nrasq61r immunostains, and molecular analyses by either targeted next-generation or direct sequencing, were performed on available archival materials. Results: Molecular testing detected mutations in KIT (44%), BRAF (25%), NF1 (22%), TP53 (17%), NRAS (9%) and TERT promoter (9%). Co-mutation of KIT and NF1 and of KIT and NRAS were identified in two and one cases, respectively. KIT mutations were significantly associated with better progression-free survival in univariate analyses. In multivariate analyses CD117 expression was significantly associated with better progression-free survival. Tumour thickness was significantly associated with worse progression-free and overall survival, and perineural invasion significantly correlated with reduced melanoma-specific survival and reduced overall survival. Cases were from multiple centres and only a subset of samples was available for molecular testing. Conclusions: KIT mutations and CD117 overexpression are markers of better progression-free survival. In addition to its prognostic value, molecular testing may identify cases that might respond to targeted agents or immunotherapeutic approaches.

AB - Background: Few studies have addressed prognostic markers and none has correlated molecular status and prognosis in vulvar melanomas. Objectives: To evaluate the clinicopathological features of 95 cases of vulvar melanoma. Methods: p53, CD117, Ki-67, neurofibromin, brafv600e and nrasq61r immunostains, and molecular analyses by either targeted next-generation or direct sequencing, were performed on available archival materials. Results: Molecular testing detected mutations in KIT (44%), BRAF (25%), NF1 (22%), TP53 (17%), NRAS (9%) and TERT promoter (9%). Co-mutation of KIT and NF1 and of KIT and NRAS were identified in two and one cases, respectively. KIT mutations were significantly associated with better progression-free survival in univariate analyses. In multivariate analyses CD117 expression was significantly associated with better progression-free survival. Tumour thickness was significantly associated with worse progression-free and overall survival, and perineural invasion significantly correlated with reduced melanoma-specific survival and reduced overall survival. Cases were from multiple centres and only a subset of samples was available for molecular testing. Conclusions: KIT mutations and CD117 overexpression are markers of better progression-free survival. In addition to its prognostic value, molecular testing may identify cases that might respond to targeted agents or immunotherapeutic approaches.

UR - http://www.scopus.com/inward/record.url?scp=85032930723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032930723&partnerID=8YFLogxK

U2 - 10.1111/bjd.15836

DO - 10.1111/bjd.15836

M3 - Article

C2 - 28734009

AN - SCOPUS:85032930723

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

ER -